PIM1 kinase as a promise of targeted therapy in prostate cancer stem cells (Review)
- Authors:
- Yingqiu Xie
- Samat Bayakhmetov
-
Affiliations: Department of Biology, Nazarbayev University School of Science and Technology, Astana 010000, Republic of Kazakhstan - Published online on: November 9, 2015 https://doi.org/10.3892/mco.2015.673
- Pages: 13-17
This article is mentioned in:
Abstract
Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 22:232–240. 1972. View Article : Google Scholar : PubMed/NCBI | |
Lawson DA and Witte ON: Stem cells in prostate cancer initiation and progression. J Clin Invest. 117:2044–2050. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
Stegmeier F, Warmuth M, Sellers WR and Dorsch M: Targeted cancer therapies in the twenty-first century: Lessons from imatinib. Clin Pharmacol Ther. 87:543–552. 2010. View Article : Google Scholar : PubMed/NCBI | |
Nawijn MC, Alendar A and Berns A: For better or for worse: The role of Pim-1 oncogenes in tumorigenesis. Nat Rev Cancer. 11:23–34. 2011. View Article : Google Scholar : PubMed/NCBI | |
Arunesh GM, Shanthi E, Krishna MH, Sooriya Kumar J and Viswanadhan VN: Small molecule inhibitors of Pim-1 kinase: July 2009 to February 2013 patent update. Expert Opin Ther Pat. 24:5–17. 2014. View Article : Google Scholar : PubMed/NCBI | |
Brault L, Gasser C, Bracher F, Huber K, Knapp S and Schwaller J: PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 95:1004–1015. 2010. View Article : Google Scholar : PubMed/NCBI | |
Hoover D, Friedmann M, Reeves R and Magnuson NS: Recombinant human pim-1 protein exhibits serine/threonine kinase activity. J Biol Chem. 266:14018–14023. 1991.PubMed/NCBI | |
Saris CJ, Domen J and Berns A: The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 10:655–664. 1991.PubMed/NCBI | |
Kim J, Roh M and Abdulkadir SA: Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer. 10:2482010. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML and Abdulkadir SA: Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 29:2477–2487. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bullock AN, Debreczeni J, Amos AL, Knapp S and Turk BE: Structure and substrate specificity of the Pim-1 kinase. J Biol Chem. 280:41675–41682. 2005. View Article : Google Scholar : PubMed/NCBI | |
Jacobs MD, Black J, Futer O, Swenson L, Hare B, Fleming M and Saxena K: Pim-1 ligand bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem. 280:13728–13734. 2005. View Article : Google Scholar : PubMed/NCBI | |
Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H and Qiu Y: The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. 25:70–78. 2006.PubMed/NCBI | |
Eichmann A, Yuan L, Bréant C, Alitalo K and Koskinen PJ: Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene. 19:1215–1224. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bachmann M and Möröy T: The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 37:726–730. 2005. View Article : Google Scholar : PubMed/NCBI | |
Merkel AL, Meggers E and Ocker M: PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs. 21:425–436. 2012. View Article : Google Scholar : PubMed/NCBI | |
Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, et al: ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PLoS One. 6:e281622011. View Article : Google Scholar : PubMed/NCBI | |
Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J and Magnuson NS: Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta. 1593:45–55. 2002. View Article : Google Scholar : PubMed/NCBI | |
Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M and Koskinen J: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Letters. 571:43–49. 2004. View Article : Google Scholar : PubMed/NCBI | |
Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, et al: The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 283:3349–3356. 2008. View Article : Google Scholar : PubMed/NCBI | |
Xie Y, Burcu M, Linn DE, Qiu Y and Baer MR: Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol. 78:310–318. 2010. View Article : Google Scholar : PubMed/NCBI | |
Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP and Schuetz JD: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 279:24218–24225. 2004. View Article : Google Scholar : PubMed/NCBI | |
Guo S, Mao X, Chen J, Huang B, Jin C, Xu Z and Qiu S: Overexpression of Pim-1 in bladder cancer. J Exp Clin Cancer Res. 29:1612010. View Article : Google Scholar : PubMed/NCBI | |
Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, et al: A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 16:403–412. 2014. View Article : Google Scholar : PubMed/NCBI | |
Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature. 412:822–826. 2001. View Article : Google Scholar : PubMed/NCBI | |
Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, et al: Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 10:309–319. 2006. View Article : Google Scholar : PubMed/NCBI | |
Linn DE, Yang X, Xie Y, Alfano A, Deshmukh D, Wang X, Shimelis H, Chen H, Li W, Xu K, et al: Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. J Biol Chem. 287:22959–22968. 2012. View Article : Google Scholar : PubMed/NCBI | |
Huang CK, Luo J, Lee SO and Chang C: Concise review: Androgen receptor differential roles in stem/progenitor cells including prostate, embryonic, stromal and hematopoietic lineages. Stem Cells. 32:2299–2308. 2014. View Article : Google Scholar : PubMed/NCBI | |
Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu H, Müller-Newen G and Jove R: Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 74:1227–1237. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML and Abdulkadir SA: Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 29:2477–2487. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Wang Z, Li X and Magnuson NS: Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 27:4809–4819. 2008. View Article : Google Scholar : PubMed/NCBI | |
Aksoy I, Sakabedoyan C, Bourillot PY, Malashicheva AB, Mancip J, Knoblauch K, Afanassieff M and Savatier P: Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3. Stem Cells. 25:2996–3004. 2007. View Article : Google Scholar : PubMed/NCBI | |
Cartwright P, McLean C, Sheppard A, Rivett D, Jones K and Dalton S: LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development. 132:885–896. 2005. View Article : Google Scholar : PubMed/NCBI | |
Li Y, McClintick J, Zhong L, Edenberg HJ, Yoder MC and Chan RJ: Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4. Blood. 105:635–637. 2005. View Article : Google Scholar : PubMed/NCBI | |
Brady JJ, Li M, Suthram S, Jiang H, Wong WH and Blau HM: Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq. Nat Cell Biol. 15:1244–1252. 2013. View Article : Google Scholar : PubMed/NCBI | |
Tu ML, Wang HQ, Sun XD, Chen LJ, Peng XC, Yuan YH, Li RM, Ruan XZ, Li DS, Xu YJ and Ke ZJ: Pim-1 is up-regulated by shear stress and is involved in shear stress-induced proliferation of rat mesenchymal stem cells. Life Sci. 88:233–238. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhao Y, Hu J, Buckingham B, Pittenger MF, Wu ZJ and Griffith BP: Pim-1 kinase cooperates with serum signals supporting mesenchymal stem cell propagation. Cells Tissues Organs. 199:140–149. 2014. View Article : Google Scholar : PubMed/NCBI | |
An N, Lin YW, Mahajan S, Kellner JN, Wang Y, Li Z, Kraft AS and Kang Y: Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells. 31:1202–1212. 2013. View Article : Google Scholar : PubMed/NCBI | |
Li L, Piloto O, Kim KT, Ye Z, Nguyen HB, Yu X, Levis M, Cheng L and Small D: FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Nat Cell Biol. 137:64–75. 2007. | |
Chu SH, Heiser D, Li L, Kaplan I, Collector M, Huso D, Sharkis SJ, Civin C and Small D: FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell. 11:346–358. 2012. View Article : Google Scholar : PubMed/NCBI | |
Natarajan K, Xie Y, Burcu M, Linn DE, Qiu Y and Baer MR: Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One. 8:e746532013. View Article : Google Scholar : PubMed/NCBI | |
Mohsin S, Khan M, Nguyen J, Alkatib M, Siddiqi S, Hariharan N, Wallach K, Monsanto M, Gude N, Dembitsky W and Sussman MA: Rejuvenation of human cardiac progenitor cells with Pim-1 kinase. Circ Res. 113:1169–1179. 2013. View Article : Google Scholar : PubMed/NCBI | |
Linn DE, Yang X, Sun F, Alkatib M, Siddiqi S, Hariharan N, Wallach K, Monsanto M, Gude N, Dembitsky W and Sussman MA: A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer. 1:908–916. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD and Sorrentino BP: Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA. 99:12339–12344. 2002. View Article : Google Scholar : PubMed/NCBI | |
Foster BA, Gangavarapu KJ, Mathew G, Azabdaftari G, Morrison CD, Miller A and Huss WJ: Human prostate side population cells demonstrate stem cell properties in recombination with urogenital sinus mesenchyme. PLoS One. 8:e550622013. View Article : Google Scholar : PubMed/NCBI | |
Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI | |
Linn DE: The role of Pim-1 kinases in advanced prostate cancer therapeutic resistance. Ph.D. dissertation. University of Maryland School of Medicine. | |
Brumbaugh J, Hou Z, Russell JD, Howden SE, Yu P, Ledvina AR, Coon JJ and Thomson JA: Phosphorylation regulates human OCT4. Proc Natl Acad Sci USA. 109:7162–7168. 2012. View Article : Google Scholar : PubMed/NCBI | |
Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cázares H, Eberhart CG, et al: c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA. 108:9951–9956. 2011. View Article : Google Scholar : PubMed/NCBI | |
van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W and Jenster G: Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One. 6:e267532011. View Article : Google Scholar : PubMed/NCBI | |
Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, et al: The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 34:2517–2532. 2014. View Article : Google Scholar : PubMed/NCBI | |
Xie Y, Lu W, Liu S, Yang Q, Carver BS, Li E, Wang Y, Fazli L, Gleave M and Chen Z: Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer. Mol Endocrinol. 28:1629–39. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB and Jain A: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 8:2882–2893. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, et al: PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst. 107:dju4072014. View Article : Google Scholar : PubMed/NCBI |